CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.

By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.

Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration

Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.

The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada

(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.